Lexaria to Examine Potential Role of DehydraTECH-CBD in Diabetes Control and Weight Loss

Lexaria Bioscience (Nasdaq:LEXX) will initiate a human clinical study to investigate the potential role of its proprietary DehydraTECH-CBD in diabetes control and weight loss. Lexaria has previously demonstrated lowered blood glucose, triglyceride and blood urea nitrogen levels, and lowered overall body weight in two separate studies of obese diabetic-conditioned animals.

Study design is currently underway, and Lexaria intends to conduct the study at the same medical research hospital in Europe that it has utilized for its recent human clinical hypertension studies.

Highlights

  • Lexaria intends to use a cost-effective approach to complete research at a fraction of the cost of US-based registered study programs.
  • The company hopes to determine whether DehydraTECH-CBD might be effective in blood-sugar control in humans, and its potential for the treatment of diabetes and its complications.
  • DehydraTECH is a patented drug delivery formulation and processing platform technology that is designed to improve the way active molecules enter the bloodstream upon oral ingestion.

About Lexaria Bioscience

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

 

 

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article

 

About the Author

Lexaria to Examine Potential Role of DehydraTECH-CBD in Diabetes Control and Weight Loss

Editor Prism MarketView